Latest news and press releases about iBio, Inc. (IBIO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis.
Price
| Price | $1.18 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.43 |
| EV / EBITDA | -3.95 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -38.55% |
| Return on Invested Capital | -39.97% |
| Return on Assets | -33.34% |
| Gross Margin | 100.00% |
| Operating Margin | -35141.00% |
| Net Margin | -33044.00% |
Related companies: ANTX · BOLD · CVKD · INTS · ITRM · KLTO · PLUR
Explore sector: Healthcare · Biotechnology
More sections of IBIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks